You are here

zenocutuzumab

FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri after brief delay

Fierce Pharma

Wed, 12/4/24 - 11:13 pm

FDA delays decision on Merus' first-in-class cancer drug by 3 months

Fierce Biotech

Tue, 11/5/24 - 10:03 am

ASCO: Merus' gene-targeting cancer drug shrinks tumors. Will execs go it alone or partner?

Fierce Biotech

Tue, 06/7/22 - 10:16 am

NRG1 fusion-positive cancer

Merus charts early promise for cancer drug targeting NRG1 fusions

Fierce Biotech

Mon, 10/28/19 - 10:40 am

bispecific antibodies